{"name":"Precigen, Inc","slug":"precigen-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Zopapogene imadenovec (Zopa)","genericName":"Zopapogene imadenovec (Zopa)","slug":"zopapogene-imadenovec-zopa","indication":"Metastatic melanoma","status":"marketed"}]}],"pipeline":[{"name":"Zopapogene imadenovec (Zopa)","genericName":"Zopapogene imadenovec (Zopa)","slug":"zopapogene-imadenovec-zopa","phase":"marketed","mechanism":"Zopapogene imadenovec is an oncolytic adenovirus engineered to express an immunostimulatory transgene that replicates in tumor cells and triggers anti-tumor immune responses.","indications":["Metastatic melanoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOQ0x3MDVfYkdFRjlWNERjUUtaN25jc1ZaUUhBYm5qZ2dwTmRTdmM4ZnhxVGNUeGgybDVFNXZYMVh5Q3BBdFJtN3hha3NiczRJOU5OUi1ONmpDVVpBdEJnWjhHemVXYWJ1Y3hSV0tJTk5rd2MxSWFBZEFSelNKNzFsMl93NGg4X2UweTFzQUI0TXE2cVFnMTJoaG9QS0VZR2sxdWVnMEhra1BYMUpKeXMyMXR3TkVrbGVsOWlzWk11TWIydw?oc=5","date":"2026-03-26","type":"pipeline","source":"Benzinga","summary":"Olaplex, Kodiak Sciences, Precigen And Other Big Stocks Moving Higher On Thursday - Benzinga","headline":"Olaplex, Kodiak Sciences, Precigen And Other Big Stocks Moving Higher On Thursday","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-17","type":"pipeline","source":"simplywall.st","summary":"3 High Growth Companies With Strong Insider Ownership - simplywall.st","headline":"3 High Growth Companies With Strong Insider Ownership","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-08","type":"pipeline","source":"simplywall.st","summary":"Precigen, Inc. (NASDAQ:PGEN): Are Analysts Optimistic? - simplywall.st","headline":"Precigen, Inc. (NASDAQ:PGEN): Are Analysts Optimistic?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOTVBybXJKNDBTdDgzOU1ST2lSVUZhRFd3Z1ZwUGotYV9MN1JrZ2hDZTRUc0hxRWpVNENYdWE3UzFuSHlxX2FjRTE3YVNhakZZNFJoQmhIUzlhcEQ0NGlrczdpaWpzMXE1VHdGQkdHR0hsd1RiOEVVNkpvWE9sd2Ztc09aVmd0MkR3cUNWSVNSemFpSzh2UjVtS2kyQzZxNWRxSWUzQmRn?oc=5","date":"2025-12-03","type":"pipeline","source":"Citeline News & Insights","summary":"2026’s Sales Growth Winners And Losers - Citeline News & Insights","headline":"2026’s Sales Growth Winners And Losers - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNeUFYYjZudTNnbUFlRUtSZ1lTVmFvRkpDaHg5eWE5UHREQUh0TU9BMWtfbkhYWFlXaG9HLTRhNm1QdkpHckZZYjQwVlI4WkhIQUJBYm92MnowenR2NWtkRmc1VGkyd3F0ZEZ2SHJKOTgyZzVUR3hkdk1XTGpBNHVqYVExU3U2cV92NDR6a1FlekJLYVNx?oc=5","date":"2025-11-25","type":"deal","source":"seekingalpha.com","summary":"Precigen Is Still A Buy After The Papzimeos Rally (NASDAQ:PGEN) - seekingalpha.com","headline":"Precigen Is Still A Buy After The Papzimeos Rally (NASDAQ:PGEN)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxOMGpGZWgwMzdnTUc3Rl83b3Nidy1wckpHVFhEV1luT0xWNXJhbXBKdThBYmJOcVo5WURMNWlMdjJkb0tUdGlvNzBVb2VaTE5yV0xxWG1vc3JDbmlWUXdfOWZJM1FtaVdvdXlqV2tyMTFqNndQQl9BUG9KcEdrMXlwX2hnU1ZxSkZSSXZCNnpkVUg5dDQ1LS1wc0NVLTNITUhuNkFiMjFZQnAwQW52X1UyTzZJSDdNN1d3LURlQU5mVFIweWlVYTRsUTZR?oc=5","date":"2025-11-13","type":"earnings","source":"prnewswire.com","summary":"Precigen Reports Third Quarter 2025 Financial Results and Business Updates - prnewswire.com","headline":"Precigen Reports Third Quarter 2025 Financial Results and Business Updates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOSERNUDY2bFhnblczeExBQzNKNVdlWXF0OVFjWHFJcDdULXNJWDliTkxYQkhMc2lnWlBUT3FZY1cybWdNMXlqS3RrM2VHTFJiaDlnRUEzOTZCMTBuWW1fYWlXTzY4UFpYNmZCZHJLUXEtbi1jYXVJTVdob0xnMzdxeE1QVVJ6UGtCdWdWZjd2NmRmbGc1X2NfbmNn?oc=5","date":"2025-09-12","type":"regulatory","source":"Pharma Voice","summary":"4 years from clinic to approval — Precigen’s ‘unprecedented’ FDA nod and what comes next - Pharma Voice","headline":"4 years from clinic to approval — Precigen’s ‘unprecedented’ FDA nod and what comes next","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxOaEZ6U2dsekZUMENTZGpjcmd0a0ltblFMNDY5TnpJQ0ZLQVR3MDRPWGlfSFNCcmJqWmJ3VC1LeGZIRjRNWmRTRzgtc3RfVEp0amFNc2ZCMXJLdUYzTnFteElzMGRwUjUwMW83b0JzeXZRUFkySnFIeDNWeE5aZEdBOHJTeERvRlZjM1cxaQ?oc=5","date":"2025-08-15","type":"regulatory","source":"Contract Pharma","summary":"FDA Fully Approves Precigen’s Papzimeos - Contract Pharma","headline":"FDA Fully Approves Precigen’s Papzimeos","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxOb1NLR212RlJKakJ4cEVTTTRHNTR6OFB6cXU2NC0yYzdrV05IZVdCY29NR0xySm9CTVpZd21tYS01T3pHRnN6YXJUMUpKa2JyYktEa3hKQkxKUTI0ZDhUdGc0T01mbV9sb19pM2R4Qnkzc3dzMWtjRXJSeVFNcUJwOGxGZXZCcmZXRTVvamlUWVpHUl9xRk1sd2loQnpoRmI4UFpQNGM4Tk1iMHBiQ0pEVlNaeUxQMjVUS0dzU09JMC1vU0diYUQxU05Zd3BMMVZfNFhGdk1CNTdHMG43ZFE?oc=5","date":"2025-08-15","type":"regulatory","source":"Reuters","summary":"Precigen shares jump after US FDA approves first therapy for rare respiratory disease - Reuters","headline":"Precigen shares jump after US FDA approves first therapy for rare respiratory disease","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxNMHZ2ODh6NmMwdXdEaklqLVgwdFo0ZzdkMVZXMnMtU1N3eDliZGRGXzlFRnphaWVZdHN1UUl2YU5tZE9NQjd5RjJTN1ZoSDl2OGgtSThveC1WWThkNURGckJ4QlpjeE0tU2pXNW53T3BiN1paZ09XZTNUMWNSaDY4a0p3?oc=5","date":"2025-08-15","type":"regulatory","source":"pharmaphorum","summary":"FDA clears Precigen's rare tumour immunotherapy - pharmaphorum","headline":"FDA clears Precigen's rare tumour immunotherapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPWnp2NHdLN0VMZk1Ucmg2RThLd1pkT05WTW1JS0cydlVnandkYzZhVG1xOS1jcFUyajVhakhGVUh0LWk5V2tZWW5tc3pJWGIwaHJSUXdLRjdtdXJYeVp5d0p2LWdDbmZEajM2cVhKUXpXeUU3V1Z6dEJ3RzlNNjc3bjhMUXN1cFpjU3U0Y0VGYUprRzZaeFZrTTN1ay1Hbktp?oc=5","date":"2025-08-15","type":"regulatory","source":"seekingalpha.com","summary":"Precigen: This Billion-Dollar Approval Is Still Undervalued (NASDAQ:PGEN) - seekingalpha.com","headline":"Precigen: This Billion-Dollar Approval Is Still Undervalued (NASDAQ:PGEN)","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxOYW1feWxfOUxPMWRmQmxvWV9IWGhvMzlSUjlFUTdhUHBHaFdiYUVySGZIUzNtNVFhaF9Jb0RHN2h5Q25odkZ0VFhQd2Q4WElZOXhVNy13WDV2NzBzR2tpbEJKU05NaktzWnc1T3llenEtMUpyOGdrUVN0d2NELTRaQjA0aFJlV2lOcHVGUk5LSV9hYk51WFBfeEJGcVhRYk43QUJrS005VjFlNjFkbEE?oc=5","date":"2025-06-25","type":"pipeline","source":"Medical Marketing and Media","summary":"Precigen chief commercial officer: How AI is impacting rare disease marketing - Medical Marketing and Media","headline":"Precigen chief commercial officer: How AI is impacting rare disease marketing","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}